Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.

Autor:	Zeytinoglu M; Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, AMB M267, Chicago, IL 60637, USA. Electronic address: mzeytinoglu@uchicago.edu., Naaman SC; Section of General Internal Medicine, Department of Medicine, University of Chicago, 355 East Grand Street, Chicago, IL 60611, USA., Dickens LT; Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, AMB M267, Chicago, IL 60637, USA.
Jazyk:	angličtina
Zdroj:	Endocrinology and metabolism clinics of North America [Endocrinol Metab Clin North Am] 2021 Jun; Vol. 50 (2), pp. 205-222.
DOI:	10.1016/j.ecl.2021.03.004
Abstrakt:	Denosumab (DMAB) is a potent antiresorptive treatment used for treatment of osteoporosis and low bone mineral density (BMD) in those at high risk for fracture. In postmenopausal women with osteoporosis, DMAB treatment for 10 years has been studied, with results showing continued gains in BMD, sustained fracture risk reduction, and low risk of adverse events. However, upon discontinuation of DMAB, there is a rapid reversal of effect, with increase in bone turnover, loss of BMD, and in a subset of patients, a greater risk for multiple vertebral fractures. Competing Interests: Disclosure M. Zeytinoglu, L. Dickens, and S. Naaman have no disclosures to report. (Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu